19:03 , Oct 18, 2017 |  BC Innovations  |  Translation in Brief

Predicting Parkinson’s progression

A team from GNS Healthcare Inc. and the University of Rochester has demonstrated that two SNPs may be able to predict how quickly Parkinson’s disease patients will progress. The results could help personalize medical care...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Eisai, General Electric, Sumitomo Chemical deal

Eisai and Nihon Medi-Physics Co. Ltd., a JV between GE and Sumitomo, partnered to improve diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan. The companies will share information on DLB. Nihon markets...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Clinical News

DaTscan: Phase IV data

An open-label, international Phase IV trial in 273 patients with clinically uncertain Parkinsonian syndrome showed that a significantly greater proportion of patients who underwent DaTscan imaging reported changes in diagnosis compared to the no imaging...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Company News

General Electric sales and marketing update

General Electric's GE Healthcare unit launched its DaTscan ioflupane I123 Injection for the visualization of dopamine transporter (DaT) distribution within the striata by single photon emission computed tomography (SPECT) imaging in patients suspected to have...
07:00 , Apr 4, 2011 |  BioCentury  |  Finance

Eleventh Hour Push

A last minute surge led by large cap stocks enabled biotech indices to post a strong performance for the first quarter. Prior to that, biotech had been relatively flat or down for most of the...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Clinical News

DaTscan ioflupane I123 Injection regulatory update

FDA approved an NDA from GE's GE Healthcare unit for DaTscan ioflupane I123 injection for the visualization of dopamine transporter (DaT) distribution within the striata by single photon emission computed tomography (SPECT) imaging in patients...
00:13 , Jan 15, 2011 |  BC Extra  |  Company News

GE's imaging agent approved

FDA approved an NDA from GE Healthcare for DaTscan ioflupane I123 injection to visualize dopamine transporter (DaT) distribution within the striata by single photon emission computed tomography (SPECT) imaging in patients suspected to have Parkinson's...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Clinical News

DaTSCAN ioflupane I123 Injection regulatory update

GE's GE Healthcare unit said the European Federation of the Neurological Societies published updated guidelines recommending DaTSCAN ioflupane I123 injection for the diagnosis and management of Alzheimer's disease (AD). The radiopharmaceutical agent is approved in...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Clinical News

DaTSCAN ioflupane I123 Injection regulatory update

FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 11-2, with 1 abstention, that available data support the risk-benefit profile of DaTSCAN ioflupane I123 injection from General Electric's GE Healthcare unit. The company is...
07:00 , Aug 17, 2009 |  BioCentury  |  Regulation

DaT's good enough

By backing DaTSCAN ioflupane I123 injection from GE Healthcare last week, an FDA panel indicated that a molecular imaging agent that allows physicians to see abnormal changes in the brain has clinical value, and that...